TABLE 2.
Clinical presentation and characteristics of the 26 recipients with BCa
| Characteristic | Result |
|---|---|
| Median (range) body temp (°C) | 38.2 (36.7–40.2) |
| Median (range) time to BC onset following allo-HSCT (days) | 33 (2–242) |
| Median (range) duration of prior antifungal exposureb (days) | 33 (4–137) |
| No. (%) of patients with the following characteristicsc: | |
| Antifungal agents used when BC developedd | |
| Micafungin | 17 |
| Liposomal amphotericin B | 5 |
| Itraconazole | 2 |
| Voriconazole | 2 |
| BC onset within 100 days following allo-HSCT | 22 (85) |
| BC onset before engraftment (neutrophil count, <500/μl) | 8 (31) |
| Septic shock at BC onset | 5 (19) |
| Systemic steroid (PSL at ≥20 mg/day) administration | 17 (65) |
| aGVHD of grade 2 or greater at BC onset | 11 (42) |
| Catheter-related candidemia | 9/22 (41) |
| Endophthalmitis | 3/15 (20) |
| BDG concn of <11 pg/ml (cutoff) | 11 (42) |
| Death within 30 days after BC onset | 10 (38) |
a
BC, breakthrough candidemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; PSL, prednisone; aGVHD; acute graft-versus-host disease.
b
The duration of prior antifungal exposure is the duration of antifungal agent administration when breakthrough candidemia developed.
c
Data are for the 26 patients with BC.
d
The distribution of the antifungal agents used when BC developed was different from that of the antifungal agents used at day 0 (Table 1) because for some patients the clinicians changed the antifungal agents that were used during transplantation.